Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEPHIR: Imaging to Predict T-DM1 Response in HER2+ Breast Cancer
NCT01565200Phase 2Completed
- Sponsor
- Institut Jules Bordet
- Start
- May 2012
- Primary completion
- Jul 2017
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of trastuzumab emtansine in breast cancer, sponsored by Institut Jules Bordet. Started May 2012; status: completed.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01565200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01565200.